✦ LIBER ✦

Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations

✍ Scribed by Annemieke Aartsma-Rus; Ivo Fokkema; Jan Verschuuren; Ieke Ginjaar; Judith van Deutekom; Gert-Jan van Ommen; Johan T. den Dunnen

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 176 KB
Volume: 30
Category: Article
ISSN: 1059-7794
DOI: 10.1002/humu.20918

No coin nor oath required. For personal study only.

✦ Synopsis

Antisense-mediated exon skipping aiming for reading frame restoration is currently a promising therapeutic application for Duchenne muscular dystrophy (DMD). This approach is mutation specific, but as the majority of DMD patients have deletions that cluster in hotspot regions, the skipping of a small number of exons is applicable to relatively large numbers of patients. To assess the actual applicability of the exon skipping approach, we here determined for deletions, duplications and point mutations reported in the Leiden DMD mutation database, which exon(s) should be skipped to restore the open reading frame. In theory, single and double exon skipping would be applicable to 79% of deletions, 91% of small mutations, and 73% of duplications, amounting to 83% of all DMD mutations. Exon 51 skipping, which is being tested in clinical trials, would be applicable to the largest group (13%) of all DMD patients. Further research is needed to determine the functionality of different in-frame dystrophins and a number of hurdles has to be overcome before this approach can be applied clinically.

📜 SIMILAR VOLUMES

In vivo comparison of 2′-O-methyl phosph

In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping

✍ Hans A. Heemskerk; Christa L. de Winter; Sjef J. de Kimpe; Petra van Kuik-Romeij 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

## Abstract ## Background Antisense‐mediated exon skipping is a putative treatment for Duchenne muscular dystrophy (DMD). Using antisense oligonucleotides (AONs), the disrupted DMD reading frame is restored, allowing generation of partially functional dystrophin and conversion of a severe Duchenne

In vitro evaluation of novel antisense o

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy

✍ Qingsong Wang; HaiFang Yin; Patrizia Camelliti; Corinne Betts; Hong Moulton; Hyu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 471 KB

## Abstract ## Background Targeted splice modulation of pre‐mRNA transcripts by antisense oligonucleotides (AOs) can correct the function of aberrant disease‐related genes. Duchenne muscular dystrophy (DMD) arises as a result of mutations that interrupt the open‐reading frame in the DMD gene encod

Exon-skipped dystrophins for treatment o

Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: Mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics

✍ Christine Carag Krieger; Nishant Bhasin; Manorama Tewari; Andre E. X. Brown; Dan 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 842 KB

Exon skipping and reading through stop c

Exon skipping and reading through stop codons: two research approaches for a therapy of Duchenne muscular dystrophy. Monaco, 17–18 January, 2004

✍ Guenter Scheuerbrandt 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Exon skipping to change Duchenne into Becker dystrophy The exon-skipping technique tries to change a Duchenne into a Becker mutation. If a deletion or a point mutation disturbs the reading frame, and thus causes Duchenne dystrophy, the reading frame can be restored by removing one or more exons